The diagnosis of the small resectable pancreatic carcinoma

Ariyama, Joe; Shirakabe, H; Ikenobe, Haruo; Kurosawa, Atsushi; Owman, T

doi:10.1016/s0009-9260(77)80160-8

Cited by 30 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The largest cyst was 6 × 3 mm in greatest dimension and the other smaller cysts with pancreatic tissue between the two cysts. We noted both normal-appearing epithelial tissue and tissue showing different degrees of cellular dysplasia, atypia and carcinoma in situ, even within the same cyst, consistent with there being a progression of pathology from normal tissue to panIN 1 through panIN 4 and frank neoplasm" Remarkably, a few pancreatic ducts within the intact parenchyma close to the cysts and up to 3 mm away from them also showed a focal or multifocal epithelial abnormality and carcinoma-in situ changes (17)(18)(19)(20). A 2 mm to 3 mm thin fibrous tissue mantle surrounded the largest cyst.…”

Section: Casesupporting

confidence: 52%

Are there Hidden (Latent, Silent, Occult) Pancreatic Cancers?

Pour¹

2017

J Mol Biomark Diagn

View full text Add to dashboard Cite

Section: Casesupporting

confidence: 52%

Are there Hidden (Latent, Silent, Occult) Pancreatic Cancers?

Pour¹

2017

J Mol Biomark Diagn

View full text Add to dashboard Cite

“…33 Data from independent experiments were pooled for statistical analysis. At week 8, when the control tumors reached approximately 2000 mm 3 , the mice were killed. For the in vivo transduction we used a preestablished xenograft model.…”

Section: Invasion Assaysmentioning

confidence: 99%

“…3 New vessel formation (angiogenesis) is a critical step in cancer progression. Clinical data have demonstrated that anti-vascular endothelial growth factor (VEGF) therapy with bevacizumab (an anti-VEGF specific antibody) is efficacious when combined with chemotherapy in colorectal and lung cancer.…”

Section: Introductionmentioning

confidence: 99%

“…For the in vivo transduction therapy experiments, tumors were generated by s.c. injection of 3 Â 10 6 cells in 300 ml of culture medium containing 10% Matrigel into the dorsal surface of mice (b-d). Tumors were allowed to develop for 5-7 days to about 100 mm 3 volume, and then mice were divided into three experimental groups. Each mouse received intratumoral (i.t.)…”

mentioning

confidence: 99%

See 1 more Smart Citation

Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer

Lefter

Dima²,

Sunamura

et al. 2008

Cancer Gene Ther

View full text Add to dashboard Cite

In this study, we addressed the hypothesis that transcriptional suppression of erythroblastosis virus E26 oncogene homolog 1 (ETS-1) is an efficient therapeutic approach to pancreatic adenocarcinoma by investigating the effect of ETS-1 suppression in human pancreatic cancer cells. We accomplished this by using an adenoviral vector encoding only the DNA-binding domain of wild-type ETS-1 (ETS-1 dominant negative, ETS-1-DN). ETS-1-DN decreases ETS-1-binding by competing for its binding to DNA. Adenoviralmediated transfer of ETS-1-DN (adenoviral ETS-1-DN construct, AdETS-1-DN) into pancreatic tumor cell lines did not affect their proliferation rate in vitro but did significantly inhibit their in vivo growth in nude mice. Furthermore, to test the efficacy of ETS-1-DN in vivo, we injected the AdETS-1-DN into established human pancreatic adenocarcinomas grown in nude mice. This treatment significantly reduced tumor size as compared to saline injection, without any detectable side effects. Microvessel density in mouse xenografts displayed significantly lower values in tumors in which ETS-1 was downregulated. In addition, expression of the ETS-1-DN in the pancreatic cancer cells resulted in downregulation of urokinase-type plasminogen activator (u-PA) and metalloproteinase-1 (MMP-1) expression. Taken together, these data suggest that transcriptional inactivation of ETS-1 is able to significantly affect angiogenesis and growth of pancreatic cancer. This effect may be due in part to downregulation of MMP-1 and u-PA expression. Our results suggest that ETS-1-DN is a promising candidate for antiangiogenic gene therapy in pancreatic cancer.

show abstract

“…A combination of ERCP and direct ductal aspiration for cytology is the best means of diagnosing resectable tumours (Mackie, Dhorajiwala et al 1979), having a diagnostic accuracy of 90% (Ariyama et al 1977). By this means tumours as small as 2 cm may be detected.…”

Section: Discussionmentioning

confidence: 99%